Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 210

1.

Capturing Exacerbations of Chronic Obstructive Pulmonary Disease with EXACT: A Sub-Analysis of FLAME.

Frent SM, Chapman KR, Larbig M, Mackay A, Fogel R, Gutzwiller FS, Shen S, Patalano F, Banerji D, Kostikas K, Wedzicha JA.

Am J Respir Crit Care Med. 2018 Jul 18. doi: 10.1164/rccm.201801-0038OC. [Epub ahead of print]

2.

Indacaterol/glycopyrronium versus salmeterol/fluticasone in the prevention of clinically important deterioration in COPD: results from the FLAME study.

Anzueto AR, Kostikas K, Mezzi K, Shen S, Larbig M, Patalano F, Fogel R, Banerji D, Wedzicha JA.

Respir Res. 2018 Jun 20;19(1):121. doi: 10.1186/s12931-018-0830-z.

3.

Gender-specific estimates of COPD prevalence: a systematic review and meta-analysis.

Ntritsos G, Franek J, Belbasis L, Christou MA, Markozannes G, Altman P, Fogel R, Sayre T, Ntzani EE, Evangelou E.

Int J Chron Obstruct Pulmon Dis. 2018 May 10;13:1507-1514. doi: 10.2147/COPD.S146390. eCollection 2018.

4.

Long-Term Triple Therapy De-escalation to Indacaterol/Glycopyrronium in Patients with Chronic Obstructive Pulmonary Disease (SUNSET): A Randomized, Double-Blind, Triple-Dummy Clinical Trial.

Chapman KR, Hurst JR, Frent SM, Larbig M, Fogel R, Guerin T, Banerji D, Patalano F, Goyal P, Pfister P, Kostikas K, Wedzicha JA.

Am J Respir Crit Care Med. 2018 Aug 1;198(3):329-339. doi: 10.1164/rccm.201803-0405OC.

5.

Towards development of aptamers that specifically bind to lactate dehydrogenase of Plasmodium falciparum through epitopic targeting.

Frith KA, Fogel R, Goldring JPD, Krause RGE, Khati M, Hoppe H, Cromhout ME, Jiwaji M, Limson JL.

Malar J. 2018 May 3;17(1):191. doi: 10.1186/s12936-018-2336-z.

6.

Indacaterol/glycopyrronium reduces the risk of clinically important deterioration after direct switch from baseline therapies in patients with moderate COPD: a post hoc analysis of the CRYSTAL study.

Greulich T, Kostikas K, Gaga M, Aalamian-Mattheis M, Lossi NS, Patalano F, Nunez X, Pagano VA, Fogel R, Vogelmeier CF, Clemens A.

Int J Chron Obstruct Pulmon Dis. 2018 Apr 16;13:1229-1237. doi: 10.2147/COPD.S159732. eCollection 2018.

7.

Exacerbation heterogeneity in COPD: subgroup analyses from the FLAME study.

Vogelmeier CF, Chapman KR, Miravitlles M, Roche N, Vestbo J, Thach C, Banerji D, Fogel R, Patalano F, Olsson P, Kostikas K, Wedzicha JA.

Int J Chron Obstruct Pulmon Dis. 2018 Apr 10;13:1125-1134. doi: 10.2147/COPD.S160011. eCollection 2018.

8.

Early Changes in eDiary COPD Symptoms Predict Clinically Relevant Treatment Response at 12 Weeks: Analysis from the CRYSTAL Study.

Kostikas K, Aalamian-Mattheis M, Pagano VA, Nunez X, Fogel R, Patalano F, Clemens A.

COPD. 2018 Apr;15(2):185-191. doi: 10.1080/15412555.2018.1445213. Epub 2018 Apr 16.

PMID:
29658810
9.

Efficacy, safety, and tolerability of plecanatide in patients with irritable bowel syndrome with constipation: results of two phase 3 randomized clinical trials.

Brenner DM, Fogel R, Dorn SD, Krause R, Eng P, Kirshoff R, Nguyen A, Crozier RA, Magnus L, Griffin PH.

Am J Gastroenterol. 2018 May;113(5):735-745. doi: 10.1038/s41395-018-0026-7. Epub 2018 Mar 15.

PMID:
29545635
10.

Leveraging Social Networking Sites for an Autoimmune Hepatitis Genetic Repository: Pilot Study to Evaluate Feasibility.

Comerford M, Fogel R, Bailey JR, Chilukuri P, Chalasani N, Lammert CS.

J Med Internet Res. 2018 Jan 18;20(1):e14. doi: 10.2196/jmir.7683.

11.

Correlations between FEV1 and patient-reported outcomes: A pooled analysis of 23 clinical trials in patients with chronic obstructive pulmonary disease.

Donohue JF, Jones PW, Bartels C, Marvel J, D'Andrea P, Banerji D, Morris DG, Patalano F, Fogel R.

Pulm Pharmacol Ther. 2018 Apr;49:11-19. doi: 10.1016/j.pupt.2017.12.005. Epub 2017 Dec 19. Review.

PMID:
29277690
12.

Reply to Cooper et al.: The Significance of Eosinophilic Inflammation in Chronic Obstructive Pulmonary Disease.

Roche N, Chapman KR, Vogelmeier CF, Herth FJF, Thach C, Fogel R, Olsson P, Patalano F, Banerji D, Wedzicha JA.

Am J Respir Crit Care Med. 2018 Apr 1;197(7):968-969. doi: 10.1164/rccm.201710-2027LE. No abstract available.

PMID:
29140725
13.

Dual Bronchodilation Response by Exacerbation History and Eosinophilia in the FLAME Study.

Papi A, Kostikas K, Wedzicha JA, Vogelmeier CF, Roche N, Shen S, Banerji D, Fogel R, Patalano F, Chapman KR.

Am J Respir Crit Care Med. 2018 May 1;197(9):1223-1226. doi: 10.1164/rccm.201709-1822LE. No abstract available.

PMID:
29099609
14.

Indacaterol/glycopyrronium: a dual bronchodilator for COPD.

Banerji D, Fogel R, Patalano F.

Drug Discov Today. 2018 Jan;23(1):196-203. doi: 10.1016/j.drudis.2017.10.015. Epub 2017 Oct 24. Review.

PMID:
29079130
15.

Dual Bronchodilation with Indacaterol Maleate/Glycopyrronium Bromide Compared with Umeclidinium Bromide/Vilanterol in Patients with Moderate-to-Severe COPD: Results from Two Randomized, Controlled, Cross-over Studies.

Kerwin E, Ferguson GT, Sanjar S, Goodin T, Yadao A, Fogel R, Maitra S, Sen B, Ayers T, Banerji D.

Lung. 2017 Dec;195(6):739-747. doi: 10.1007/s00408-017-0055-9. Epub 2017 Oct 9.

PMID:
28993871
16.

Efficacy of Indacaterol/Glycopyrronium in Patients with COPD Who Have Increased Dyspnea with Daily Activities.

Mahler DA, Keininger DL, Mezzi K, Fogel R, Banerji D.

Chronic Obstr Pulm Dis. 2016 Sep 9;3(4):758-768. doi: 10.15326/jcopdf.3.4.2016.0138.

17.

Reply: What Should Be the Cutoff Value of Blood Eosinophilia as a Predictor of Inhaled Corticosteroid Responsiveness in Patients with Chronic Obstructive Pulmonary Disease?

Roche N, Chapman KR, Vogelmeier CF, Herth FJF, Thach C, Fogel R, Olsson P, Patalano F, Banerji D, Wedzicha JA.

Am J Respir Crit Care Med. 2017 Nov 1;196(9):1230-1231. doi: 10.1164/rccm.201706-1105LE. No abstract available.

PMID:
28650724
18.

Response to Indacaterol/Glycopyrronium (IND/GLY) by Sex in Patients with COPD: A Pooled Analysis from the IGNITE Program.

Tsiligianni I, Mezzi K, Fucile S, Kostikas K, Shen S, Banerji D, Fogel R.

COPD. 2017 Aug;14(4):375-381. doi: 10.1080/15412555.2017.1324837. Epub 2017 Jun 8.

PMID:
28594587
19.

Epitope-specific immunotherapy targeting CD4-positive T cells in coeliac disease: two randomised, double-blind, placebo-controlled phase 1 studies.

Goel G, King T, Daveson AJ, Andrews JM, Krishnarajah J, Krause R, Brown GJE, Fogel R, Barish CF, Epstein R, Kinney TP, Miner PB Jr, Tye-Din JA, Girardin A, Taavela J, Popp A, Sidney J, Mäki M, Goldstein KE, Griffin PH, Wang S, Dzuris JL, Williams LJ, Sette A, Xavier RJ, Sollid LM, Jabri B, Anderson RP.

Lancet Gastroenterol Hepatol. 2017 Jul;2(7):479-493. doi: 10.1016/S2468-1253(17)30110-3. Epub 2017 May 11.

20.

The effect of indacaterol/glycopyrronium versus tiotropium or salmeterol/fluticasone on the prevention of clinically important deterioration in COPD.

Anzueto AR, Vogelmeier CF, Kostikas K, Mezzi K, Fucile S, Bader G, Shen S, Banerji D, Fogel R.

Int J Chron Obstruct Pulmon Dis. 2017 May 4;12:1325-1337. doi: 10.2147/COPD.S133307. eCollection 2017.

21.

Digital Cohorts Within the Social Mediome: An Approach to Circumvent Conventional Research Challenges?

Kulanthaivel A, Fogel R, Jones J, Lammert C.

Clin Gastroenterol Hepatol. 2017 May;15(5):614-618. doi: 10.1016/j.cgh.2017.02.015. No abstract available.

22.

Corrigendum: Responsiveness of Endoscopic Indices of Disease Activity for Crohn's Disease.

Khanna R, Zou G, Stitt L, Feagan BG, Sandborn WJ, Rutgeerts P, McDonald JWD, Dubcenco E, Fogel R, Panaccione R, Jairath V, Nelson S, Shackelton LM, Huang B, Zhou Q, Robinson AM, Levesque BG, D'Haens G.

Am J Gastroenterol. 2017 Jun;112(6):975. doi: 10.1038/ajg.2017.120. Epub 2017 Apr 18. No abstract available.

PMID:
28417993
23.

LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis.

Rodrigo GJ, Price D, Anzueto A, Singh D, Altman P, Bader G, Patalano F, Fogel R, Kostikas K.

Int J Chron Obstruct Pulmon Dis. 2017 Mar 17;12:907-922. doi: 10.2147/COPD.S130482. eCollection 2017. Review.

24.

Blood Eosinophils and Response to Maintenance Chronic Obstructive Pulmonary Disease Treatment. Data from the FLAME Trial.

Roche N, Chapman KR, Vogelmeier CF, Herth FJF, Thach C, Fogel R, Olsson P, Patalano F, Banerji D, Wedzicha JA.

Am J Respir Crit Care Med. 2017 May 1;195(9):1189-1197. doi: 10.1164/rccm.201701-0193OC.

25.

Quantitative methylene blue decolourisation assays as rapid screening tools for assessing the efficiency of catalytic reactions.

Kruid J, Fogel R, Limson JL.

Chemosphere. 2017 May;175:247-252. doi: 10.1016/j.chemosphere.2017.02.051. Epub 2017 Feb 12.

PMID:
28226278
26.

The Utility of Nurse-Managed Extracorporeal Life Support in an Adult Cardiac Intensive Care Unit.

Hackmann AE, Wiggins LM, Grimes GP, Fogel RM, Schenkel FA, Barr ML, Bowdish ME, Cunningham MJ, Starnes VA.

Ann Thorac Surg. 2017 Aug;104(2):510-514. doi: 10.1016/j.athoracsur.2016.11.005. Epub 2017 Feb 10.

PMID:
28193535
27.

Indacaterol/glycopyrronium versus salmeterol/fluticasone in Asian patients with COPD at a high risk of exacerbations: results from the FLAME study.

Wedzicha JA, Zhong N, Ichinose M, Humphries M, Fogel R, Thach C, Patalano F, Banerji D.

Int J Chron Obstruct Pulmon Dis. 2017 Jan 19;12:339-349. doi: 10.2147/COPD.S125058. eCollection 2017.

28.

European Heart Rhythm Association (EHRA)/European Association of Cardiovascular Prevention and Rehabilitation (EACPR) position paper on how to prevent atrial fibrillation endorsed by the Heart Rhythm Society (HRS) and Asia Pacific Heart Rhythm Society (APHRS).

Gorenek B, Pelliccia A, Benjamin EJ, Boriani G, Crijns HJ, Fogel RI, Van Gelder IC, Halle M, Kudaiberdieva G, Lane DA, Larsen TB, Lip GY, Løchen ML, Marín F, Niebauer J, Sanders P, Tokgozoglu L, Vos MA, Van Wagoner DR, Fauchier L, Savelieva I, Goette A, Agewall S, Chiang CE, Figueiredo M, Stiles M, Dickfeld T, Patton K, Piepoli M, Corra U, Marques-Vidal PM, Faggiano P, Schmid JP, Abreu A.

Europace. 2017 Feb 1;19(2):190-225. doi: 10.1093/europace/euw242. No abstract available.

PMID:
28175283
29.

Responsiveness of Endoscopic Indices of Disease Activity for Crohn's Disease.

Khanna R, Zou G, Stitt L, Feagan BG, Sandborn WJ, Rutgeerts P, McDonald JWD, Dubcenco E, Fogel R, Panaccione R, Jairath V, Nelson S, Shackelton LM, Huang B, Zhou Q, Robinson AM, Levesque BG, D'Haens G.

Am J Gastroenterol. 2017 Oct;112(10):1584-1592. doi: 10.1038/ajg.2016.580. Epub 2017 Jan 10.

PMID:
28071654
30.

Indacaterol/glycopyrronium in symptomatic patients with COPD (GOLD B and GOLD D) versus salmeterol/fluticasone: ILLUMINATE/LANTERN pooled analysis.

Vogelmeier C, Zhong N, Humphries MJ, Mezzi K, Fogel R, Bader G, Patalano F, Banerji D.

Int J Chron Obstruct Pulmon Dis. 2016 Dec 14;11:3189-3197. doi: 10.2147/COPD.S116786. eCollection 2016.

31.

Efficacy and safety of indacaterol/glycopyrronium in Japanese patients with COPD: Pooled analysis of SHINE and ARISE.

Asai K, Hirata K, Hashimoto S, Fukuchi Y, Kitawaki T, Ikeda K, Fogel R, Banerji D.

Respir Investig. 2016 Nov;54(6):428-435. doi: 10.1016/j.resinv.2016.06.006. Epub 2016 Aug 24.

PMID:
27886854
32.

European Heart Rhythm Association (EHRA)/European Association of Cardiovascular Prevention and Rehabilitation (EACPR) position paper on how to prevent atrial fibrillation endorsed by the Heart Rhythm Society (HRS) and Asia Pacific Heart Rhythm Society (APHRS).

Gorenek Chair B, Pelliccia Co-Chair A, Benjamin EJ, Boriani G, Crijns HJ, Fogel RI, Van Gelder IC, Halle M, Kudaiberdieva G, Lane DA, Bjerregaard Larsen T, Lip GY, Løchen ML, Marin F, Niebauer J, Sanders P, Tokgozoglu L, Vos MA, Van Wagoner DR; Document reviewers:, Fauchier L, Savelieva I, Goette A, Agewall S, Chiang CE, Figueiredo M, Stiles M, Dickfeld T, Patton K, Piepoli M, Corra U, Manuel Marques-Vidal P, Faggiano P, Schmid JP, Abreu A.

Eur J Prev Cardiol. 2017 Jan;24(1):4-40. Epub 2016 Nov 4. Review. No abstract available.

33.

Acoustic biosensors.

Fogel R, Limson J, Seshia AA.

Essays Biochem. 2016 Jun 30;60(1):101-10. doi: 10.1042/EBC20150011. Review.

34.

Randomised clinical trial: a phase 1, dose-ranging study of the anti-matrix metalloproteinase-9 monoclonal antibody GS-5745 versus placebo for ulcerative colitis.

Sandborn WJ, Bhandari BR, Fogel R, Onken J, Yen E, Zhao X, Jiang Z, Ge D, Xin Y, Ye Z, French D, Silverman JA, Kanwar B, Subramanian GM, McHutchison JG, Lee SD, Shackelton LM, Pai RK, Levesque BG, Feagan BG.

Aliment Pharmacol Ther. 2016 Jul;44(2):157-69. doi: 10.1111/apt.13653. Epub 2016 May 24.

35.

Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD.

Wedzicha JA, Banerji D, Chapman KR, Vestbo J, Roche N, Ayers RT, Thach C, Fogel R, Patalano F, Vogelmeier CF; FLAME Investigators.

N Engl J Med. 2016 Jun 9;374(23):2222-34. doi: 10.1056/NEJMoa1516385. Epub 2016 May 15.

36.

Developing Biosensors in Developing Countries: South Africa as a Case Study.

Fogel R, Limson J.

Biosensors (Basel). 2016 Feb 2;6(1). pii: E5. doi: 10.3390/bios6010005. Review.

37.

2015 ACC/AHA/HRS Advanced Training Statement on Clinical Cardiac Electrophysiology (A Revision of the ACC/AHA 2006 Update of the Clinical Competence Statement on Invasive Electrophysiology Studies, Catheter Ablation, and Cardioversion).

Zipes DP, Calkins H, Daubert JP, Ellenbogen KA, Field ME, Fisher JD, Fogel RI, Frankel DS, Gupta A, Indik JH, Kusumoto FM, Lindsay BD, Marine JE, Mehta LS, Mendes LA, Miller JM, Munger TM, Sauer WH, Shen WK, Stevenson WG, Su WW, Tracy CM, Tsiperfal A.

Heart Rhythm. 2016 Jan;13(1):e3-e37. doi: 10.1016/j.hrthm.2015.09.014. Epub 2015 Sep 24. No abstract available.

PMID:
26392325
38.

2015 ACC/AHA/HRS Advanced Training Statement on Clinical Cardiac Electrophysiology (A Revision of the ACC/AHA 2006 Update of the Clinical Competence Statement on Invasive Electrophysiology Studies, Catheter Ablation, and Cardioversion).

Zipes DP, Calkins H, Daubert JP, Ellenbogen KA, Field ME, Fisher JD, Fogel RI, Frankel DS, Gupta A, Indik JH, Kusumoto FM, Lindsay BD, Marine JE, Mehta LS, Mendes LA, Miller JM, Munger TM, Sauer WH, Shen WK, Stevenson WG, Su WW, Tracy CM, Tsiperfal A.

J Am Coll Cardiol. 2015 Dec 22;66(24):2767-2802. doi: 10.1016/j.jacc.2015.08.040. Epub 2015 Sep 18. Review. No abstract available.

39.

2015 ACC/AHA/HRS Advanced Training Statement on Clinical Cardiac Electrophysiology (A Revision of the ACC/AHA 2006 Update of the Clinical Competence Statement on Invasive Electrophysiology Studies, Catheter Ablation, and Cardioversion).

Zipes DP, Calkins H, Daubert JP, Ellenbogen KA, Field ME, Fisher JD, Fogel RI, Frankel DS, Gupta A, Indik JH, Kusumoto FM, Lindsay BD, Marine JE, Mehta LS, Mendes LA, Miller JM, Munger TM, Sauer WH, Shen WK, Stevenson WG, Su WW, Tracy CM, Tsiperfal A, Williams ES, Halperin JL, Arrighi JA, Awtry EH, Bates ER, Brush JE Jr, Costa S, Daniels L, Desai A, Drachman DE, Fernandes S, Freeman R, Ijioma N, Khan SS, Kuvin JT, Marine JE, McPherson JA, Mendes LA, Sivaram CA, Spicer RL, Wang A, Weitz HH; American College of Cardiology; American Heart Association; Heart Rhythm Society.

Circ Arrhythm Electrophysiol. 2015 Dec;8(6):1522-51. doi: 10.1161/HAE.0000000000000014. Epub 2015 Sep 18. No abstract available.

PMID:
26386016
40.

Treatment of Atrial Fibrillation.

Prystowsky EN, Padanilam BJ, Fogel RI.

JAMA. 2015 Jul 21;314(3):278-88. doi: 10.1001/jama.2015.7505. Review.

PMID:
26197188
41.

Drug development for airway diseases: looking forward.

Holgate S, Agusti A, Strieter RM, Anderson GP, Fogel R, Bel E, Martin TR, Reiss TF.

Nat Rev Drug Discov. 2015 Jun;14(6):367-8. doi: 10.1038/nrd4645. Epub 2015 May 22.

PMID:
26000726
42.

HRS Expert Consensus Statement on remote interrogation and monitoring for cardiovascular implantable electronic devices.

Slotwiner D, Varma N, Akar JG, Annas G, Beardsall M, Fogel RI, Galizio NO, Glotzer TV, Leahy RA, Love CJ, McLean RC, Mittal S, Morichelli L, Patton KK, Raitt MH, Ricci RP, Rickard J, Schoenfeld MH, Serwer GA, Shea J, Varosy P, Verma A, Yu CM.

Heart Rhythm. 2015 Jul;12(7):e69-100. doi: 10.1016/j.hrthm.2015.05.008. Epub 2015 May 14. No abstract available.

PMID:
25981148
43.

Same-day discharge and risks of mortality and readmission after elective ICD placement for primary prevention.

Hess PL, Greiner MA, Al-Khatib SM, Masoudi FA, Varosy PD, Fogel RI, Curtis LH, Hernandez AF.

J Am Coll Cardiol. 2015 Mar 10;65(9):955-7. doi: 10.1016/j.jacc.2014.12.032. No abstract available.

44.

QVA149 Improves Lung Function, Dyspnea, and Health Status Independent of Previously Prescribed Medications and COPD Severity: A Subgroup Analysis from the SHINE and ILLUMINATE Studies.

Chapman KR, Bateman ED, Chen H, Hu H, Fogel R, Banerji D.

Chronic Obstr Pulm Dis. 2015 Jan 1;2(1):48-60. doi: 10.15326/jcopdf.2.1.2014.0140.

45.

Message from the president.

Fogel RI.

Heart Rhythm. 2015 Jan;12(1):1-2. doi: 10.1016/j.hrthm.2014.11.023. No abstract available.

PMID:
25542712
46.

The small gastroenterology practice: how to survive in a changing world. Perspectives of a practicing clinician.

Fogel R.

Clin Gastroenterol Hepatol. 2015 Mar;13(3):419-21. doi: 10.1016/j.cgh.2014.12.003. Epub 2014 Dec 9. No abstract available.

PMID:
25500132
47.

Progress toward the prevention and treatment of atrial fibrillation: A summary of the Heart Rhythm Society Research Forum on the Treatment and Prevention of Atrial Fibrillation, Washington, DC, December 9-10, 2013.

Van Wagoner DR, Piccini JP, Albert CM, Anderson ME, Benjamin EJ, Brundel B, Califf RM, Calkins H, Chen PS, Chiamvimonvat N, Darbar D, Eckhardt LL, Ellinor PT, Exner DV, Fogel RI, Gillis AM, Healey J, Hohnloser SH, Kamel H, Lathrop DA, Lip GY, Mehra R, Narayan SM, Olgin J, Packer D, Peters NS, Roden DM, Ross HM, Sheldon R, Wehrens XH.

Heart Rhythm. 2015 Jan;12(1):e5-e29. doi: 10.1016/j.hrthm.2014.11.011. Epub 2014 Nov 18. No abstract available.

48.

Addressing unmet needs in the treatment of COPD.

Patalano F, Banerji D, D'Andrea P, Fogel R, Altman P, Colthorpe P.

Eur Respir Rev. 2014 Sep;23(133):333-44. doi: 10.1183/09059180.00004014. Review.

49.

Pooled safety analysis of the fixed-dose combination of indacaterol and glycopyrronium (QVA149), its monocomponents, and tiotropium versus placebo in COPD patients.

Wedzicha JA, Dahl R, Buhl R, Schubert-Tennigkeit A, Chen H, D'Andrea P, Fogel R, Banerji D.

Respir Med. 2014 Oct;108(10):1498-507. doi: 10.1016/j.rmed.2014.07.011. Epub 2014 Aug 4.

50.

Electrocardiographic features and prevalence of bilateral bundle-branch delay.

Tzogias L, Steinberg LA, Williams AJ, Morris KE, Mahlow WJ, Fogel RI, Olson JA, Prystowsky EN, Padanilam BJ.

Circ Arrhythm Electrophysiol. 2014 Aug;7(4):640-4. doi: 10.1161/CIRCEP.113.000999. Epub 2014 Jul 11.

PMID:
25015953

Supplemental Content

Support Center